Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
5.05
-0.15 (-2.88%)
At close: Sep 1, 2026, 4:00 PM EDT
5.07
+0.02 (0.40%)
Pre-market: Sep 2, 2026, 5:56 AM EDT
Unicycive Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
22
Market Cap
140.67M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 675.00K | -276.00K | -29.02% |
| Dec 31, 2022 | 951.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Equillium | 4.39M |
| NRx Pharmaceuticals | 3.39M |
| Connect Biopharma Holdings | 2.95M |
| Kazia Therapeutics | 1.27M |
| Inovio Pharmaceuticals | 65.34K |
| Outlook Therapeutics | -1.16M |
UNCY News
- 23 hours ago - Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 12 days ago - Unicycive Therapeutics price target raised to $15 from $13 at Benchmark - TheFly
- 16 days ago - Unicycive Therapeutics reports Q2 EPS (6c), consensus (33c) - TheFly
- 16 days ago - Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley - TheFly
- 16 days ago - Unicycive Therapeutics price target lowered to $25 from $37 at Guggenheim - TheFly
- 20 days ago - Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 20 days ago - Unicycive Therapeutics Quarterly report: Q2 2026 - Filings
- 20 days ago - Unicycive Therapeutics Earnings release: Q2 2026 - Filings